271 related articles for article (PubMed ID: 29487377)
1. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort.
Marzouka NA; Eriksson P; Rovira C; Liedberg F; Sjödahl G; Höglund M
Sci Rep; 2018 Feb; 8(1):3737. PubMed ID: 29487377
[TBL] [Abstract][Full Text] [Related]
2. The Lund Molecular Taxonomy Applied to Non-Muscle-Invasive Urothelial Carcinoma.
Marzouka NA; Eriksson P; Bernardo C; Hurst CD; Knowles MA; Sjödahl G; Liedberg F; Höglund M
J Mol Diagn; 2022 Sep; 24(9):992-1008. PubMed ID: 35853574
[TBL] [Abstract][Full Text] [Related]
3. Molecular subtype classification of urothelial carcinoma in Lynch syndrome.
Therkildsen C; Eriksson P; Höglund M; Jönsson M; Sjödahl G; Nilbert M; Liedberg F
Mol Oncol; 2018 Aug; 12(8):1286-1295. PubMed ID: 29791078
[TBL] [Abstract][Full Text] [Related]
4. Toward a molecular pathologic classification of urothelial carcinoma.
Sjödahl G; Lövgren K; Lauss M; Patschan O; Gudjonsson S; Chebil G; Aine M; Eriksson P; Månsson W; Lindgren D; Fernö M; Liedberg F; Höglund M
Am J Pathol; 2013 Sep; 183(3):681-91. PubMed ID: 23827819
[TBL] [Abstract][Full Text] [Related]
5. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathology of the luminal class of urothelial tumors.
Bernardo C; Eriksson P; Marzouka NA; Liedberg F; Sjödahl G; Höglund M
J Pathol; 2019 Nov; 249(3):308-318. PubMed ID: 31232464
[TBL] [Abstract][Full Text] [Related]
7. HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts.
Eriksson P; Sjödahl G; Chebil G; Liedberg F; Höglund M
Oncotarget; 2017 Jul; 8(30):48905-48914. PubMed ID: 28388586
[TBL] [Abstract][Full Text] [Related]
8. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
9. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification.
Sjödahl G; Eriksson P; Liedberg F; Höglund M
J Pathol; 2017 May; 242(1):113-125. PubMed ID: 28195647
[TBL] [Abstract][Full Text] [Related]
10. Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems.
Eriksson P; Aine M; Veerla S; Liedberg F; Sjödahl G; Höglund M
BMC Med Genomics; 2015 May; 8():25. PubMed ID: 26008846
[TBL] [Abstract][Full Text] [Related]
11. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
12. Molecular Subtype Profiling of Urothelial Carcinoma Using a Subtype-Specific Immunohistochemistry Panel.
Sjödahl G
Methods Mol Biol; 2018; 1655():53-64. PubMed ID: 28889377
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathology of the non-luminal Ba/Sq-like and Sc/NE-like classes of urothelial tumours: An integrated immunohistochemical analysis.
Bernardo C; Eriksson P; Marzouka NA; Liedberg F; Sjödahl G; Höglund M
Hum Pathol; 2022 Apr; 122():11-24. PubMed ID: 35108518
[TBL] [Abstract][Full Text] [Related]
14. Molecular Pathologic Subtyping of Urothelial Bladder Carcinoma in Young Patients.
Shelekhova KV; Krykow KA; Mescherjakov IA; Mitin NP
Int J Surg Pathol; 2019 Aug; 27(5):483-491. PubMed ID: 30854907
[TBL] [Abstract][Full Text] [Related]
15. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
Genitsch V; Kollár A; Vandekerkhove G; Blarer J; Furrer M; Annala M; Herberts C; Pycha A; de Jong JJ; Liu Y; Krentel F; Davicioni E; Gibb EA; Kruithof-de Julio M; Wyatt AW; Seiler R
Urol Oncol; 2019 Nov; 37(11):826-836. PubMed ID: 31585777
[TBL] [Abstract][Full Text] [Related]
16. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma.
Lindgren D; Sjödahl G; Lauss M; Staaf J; Chebil G; Lövgren K; Gudjonsson S; Liedberg F; Patschan O; Månsson W; Fernö M; Höglund M
PLoS One; 2012; 7(6):e38863. PubMed ID: 22685613
[TBL] [Abstract][Full Text] [Related]
17. GPX2 underexpression indicates poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder.
Chang IW; Lin VC; Hung CH; Wang HP; Lin YY; Wu WJ; Huang CN; Li CC; Li WM; Wu JY; Li CF
World J Urol; 2015 Nov; 33(11):1777-89. PubMed ID: 25813210
[TBL] [Abstract][Full Text] [Related]
18. [Markers of stem cells and their prognostic values for urothelial carcinomas of the urinary tract].
Osmanov YI; Kogan EA; Rapoport LM; Teodorovich OV; Gaibov JA
Urologiia; 2019 Jun; (2):40-49. PubMed ID: 31162900
[TBL] [Abstract][Full Text] [Related]
19. INHBA overexpression indicates poor prognosis in urothelial carcinoma of urinary bladder and upper tract.
Lee HY; Li CC; Huang CN; Li WM; Yeh HC; Ke HL; Yang KF; Liang PI; Li CF; Wu WJ
J Surg Oncol; 2015 Mar; 111(4):414-22. PubMed ID: 25488476
[TBL] [Abstract][Full Text] [Related]
20. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines.
Tomlinson DC; L'Hôte CG; Kennedy W; Pitt E; Knowles MA
Cancer Res; 2005 Nov; 65(22):10441-9. PubMed ID: 16288035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
